During myocardial ischemia, sulfonylureas partially inhibit channels opening, avoiding so the required hyperpolarization that protects the cell by impeding calcium influx (the so-called ischemic preconditioning) [8, 9]
Essential mitigation strategies include fasting morning blood draws, 24-h urine collections to integrate metabolite production over diurnal cycles, dietary adjustment in statistical models, and repeated measurements to capture intra-individual variability
In fact, these pathways mediate the metabolic actions of MOTS-c [4]
These lawsuits allege that the drug has caused serious side effects such as pancreatic inflammation, thyroid cancer, kidney failure, and gastrointestinal issues, including stomach paralysis, which Novo Nordisk failed to warn patients about